| Urothelial Carcinoma
Balversa vs Bavencio
Side-by-side clinical, coverage, and cost comparison for urothelial carcinoma.Deep comparison between: Balversa vs Bavencio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBavencio has a higher rate of injection site reactions vs Balversa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Bavencio but not Balversa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Balversa
Bavencio
At A Glance
Oral
Once daily
FGFR inhibitor
IV infusion
Every 2 weeks
PD-L1 blocking antibody
Indications
- Urothelial Carcinoma
- Merkel cell carcinoma
- Urothelial Carcinoma
- Renal Cell Carcinoma
Dosing
Urothelial Carcinoma Starting dose 8 mg (two 4 mg tablets) orally once daily; increase to 9 mg (three 3 mg tablets) once daily at 14 to 21 days if serum phosphate level criteria are met and tolerability allows; continue until disease progression or unacceptable toxicity.
Merkel cell carcinoma, Urothelial Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks in combination with axitinib 5 mg orally twice daily (12 hours apart) with or without food until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>20%) Increased phosphate, nail disorders, stomatitis, diarrhea, increased creatinine, increased alkaline phosphatase, increased alanine aminotransferase, decreased hemoglobin, decreased sodium, increased aspartate aminotransferase, fatigue, dry mouth, dry skin, decreased phosphate, decreased appetite, dysgeusia, constipation, increased calcium, dry eye, palmar-plantar erythrodysesthesia syndrome, increased potassium, alopecia, central serous retinopathy
Serious Urinary tract infection, hematuria, hyponatremia, acute kidney injury, central serous retinopathy, general physical health deterioration
Most common (>=20%) fatigue, musculoskeletal pain, diarrhea, hypertension, nausea, rash, infusion-related reaction, cough, constipation, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, hepatotoxicity, dyspnea, abdominal pain, urinary tract infection, headache
Serious immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, myocarditis, neurological toxicities), infusion-related reactions, complications of allogeneic HSCT, major adverse cardiovascular events
Postmarketing neutropenia, sclerosing cholangitis
Pharmacology
Erdafitinib is a kinase inhibitor that binds to and inhibits enzymatic activity of FGFR1, FGFR2, FGFR3, and FGFR4; inhibition of FGFR phosphorylation and signaling decreases cell viability in tumor cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions.
Avelumab is a human IgG1 lambda monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors on T cells to restore anti-tumor immune responses; it also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Balversa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Bavencio
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Balversa
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Bavencio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Balversa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Bavencio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
J&J withMe Savings Program: BalversaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Bavencio.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BalversaView full Balversa profile
BavencioView full Bavencio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.